Comparative Study of Two Application Regimens of Amniotic Membrane Wound Graft In the Management of Diabetic Foot Ulcers
NCT ID: NCT01657474
Last Updated: 2013-12-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
40 participants
INTERVENTIONAL
2012-09-30
2013-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Weekly Application of EpiFix
Weekly application of EpiFix plus standard of care
Weekly application of EpiFix plus standard of care
Biweekly application of EpiFix
Biweekly application of EpiFix plus standard of care
Biweekly application of EpiFix plus standard of care
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Weekly application of EpiFix plus standard of care
Biweekly application of EpiFix plus standard of care
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Informed consent must be obtained
3. Patient's ulcer must be diabetic in origin and larger than 1cm2. Debridement will be done prior to randomization. Subject's informed consent for participating in this study, must be obtained prior to proceeding with sharp debridement.
4. Patients with Type 1 or Type 2 diabetes (criteria for the diagnosis of diabetes mellitus per ADA).
5. Ulcer must be present for a minimum of four weeks before enrollment/randomization, with documented failure of prior treatment to heal the wound. A two week run in period will precede enrollment/randomization in the trial to document the indolent nature of the wounds selected
6. Additional wounds may be present but not within 3cm of the study wound
7. Wound must be present anatomically on the plantar surface of the foot
8. Patient's ulcer must exhibit no clinical signs of infection.
9. Patient is of legal consenting age.
10. Patient is willing to provide informed consent and is willing to participate in all procedures and follow up evaluations necessary to complete the study.
11. Serum Creatine less then 3.0mg/dl
12. HbA1c less than 12%
13. Patient has adequate circulation to the affected extremity, as demonstrated by one of the following within the past 60 days:
* Dorsum transcutaneous oxygen test (TcPO2) with results ≥30mmHg, OR
* ABIs with results of ≥0.7 and ≤1.2, OR
* Doppler arterial waveforms, which are triphasic or biphasic at the ankle of affected leg
Exclusion Criteria
2. Patients whose index diabetic foot ulcers are greater than 25cm2.
3. Patients considered not in reasonable metabolic control, confirmed by an HbA1c greater than 12% within previous 90 days,
4. Patients whose serum creatinine levels are 3.0mg/dl or greater.
5. Patients with a known history of poor compliance with medical treatments.
6. Patients who have been previously randomized into this study, or are presently participating in another clinical trial
7. Patients who are currently receiving radiation therapy or chemotherapy.
8. Patients with known or suspected local skin malignancy to the index diabetic ulcer.
9. Patients diagnosed with autoimmune connective tissues diseases.
10. Non-revascularizable surgical sites
11. Active infection at site
12. Any pathology that would limit the blood supply and compromise healing;
13. Patients that have received a biomedical or topical growth factor for their wound within the previous 30 days
14. Patient who are pregnant or breast feeding
15. Patient who are taking medications that are considered immune system modulator which could affect graft incorporation.
16. Allergy to Gentamycin or Streptomycin
17. Wounds greater than one year in duration without intermittent healing
18. Wound improving greater than 20% over the first two weeks of the trial using standard of care dressing and Cam Boot
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
MiMedx Group, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Charles M. Zelen, DPM
Role: PRINCIPAL_INVESTIGATOR
Professional Education and Research Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Professional Education and Research Institute
Roanoke, Virginia, United States
Professional Education and Research Institute
Salem, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EFDFU002
Identifier Type: -
Identifier Source: org_study_id